Efficacy, safety and persistence of Ustekinumab versus Infliximab in bionaive patients with moderate to severe Crohn disease patients: a real world experience

• Main Authors: Nik Muhamad Affendi, Nik Arsyad, Xin Hui, Khoo, hilmi, ida normiha
• Format: Conference or Workshop Item
• Language: English
• Published: 2022
• Subjects: RC Internal medicine
• Online Access: http://irep.iium.edu.my/99667/3/99667_efficacy_and%20safety%20of%20per-oral.pdf; http://irep.iium.edu.my/99667/

BACKGROUND AND AIM: Ustekinumab was licenced for treatment of moderate to severe Crohn disease (CD) in Malaysia since March 2020 while Infliximab is a well-established treatment for moderate to severe CD. Our objective is to look at real- world data on efficacy, safety and persistence of Ustekinumab...